Green Cross, IVI sign MOU on Zika virus vaccine

Green Cross, IVI sign MOU on Zika virus vaccine

Green Cross, a Korean vaccine-maker, has signed a memorandum of understanding with the International Vaccine Institute to jointly develop a vaccine to prevent Zika virus, the company said Tuesday.

Under the agreement, Green Cross and its affiliate Green Cross Medical Science will share a pool of researchers, labs and instrumental techniques on vaccine development. Green Cross will also share its technical know-how on vaccine development and production while IVI offers Zika virus strains for joint research.

Zika virus infection is suspected of leading to thousands of babies being born with underdeveloped brains.

So far, there’s no preventative medicine for the virus. According to reports, experts in the U.S. are preparing for trials of a Zika vaccine in September.

“This partnership between (the pharmaceutical) industry and an international research institute will contribute in improving the global public health,” said Jerome Kim, director general of the Seoul-based institute, in a statement written in Korean.


Share this post

Leave a Reply

Your email address will not be published.